Immunocore Holdings plc - ADR

NASDAQ:IMCR   12:45:27 PM EDT
35.48
-0.27 (-0.76%)
Products

Immunocore Announces That U.S. FDA And EMA Accept Biologics License Application And Marketing Authorization Application For Tebentafusp In Metastatic Uveal Melanoma

Published: 08/24/2021 14:27 GMT
Immunocore Holdings plc - ADR (IMCR) - Immunocore Announces That U.S. Food and Drug Administration and European Medicines Agency Accept Biologics License Application and Marketing Authorization Application for Tebentafusp in Metastatic Uveal Melanoma.
Immunocore Holdings Plc - FDA Grants Priority Review to Tebentafusp for Treatment of Hla-a*02:01-positive Patients With Metastatic Uveal Melanoma.
Immunocore Holdings Plc - for Tebentafusp, Expected Prescription Drug User Fee Act Target Action Date of Feb 23, 2022.
Immunocore - Ema Committee for Medicinal Products for Human Use Will Review Tebentafusp Application Under Accelerated Assessment Procedure.